NIH Board Chair: Kennedy's New Vaccine Clinic Costs Zero Dollars

Jack Leslie, the chair of the board overseeing the National Institutes of Health Clinical Center Research Hospital, warned colleagues this month that a new clinic opened by Health Secretary Robert F. Kennedy Jr. could affect the institution's standing. Leslie made the comments during a regularly scheduled meeting, dedicating approximately six minutes to a direct critique of the secretary's recent activities.

The friction centers on a surprise ribbon-cutting ceremony held at the hospital to launch Kennedy's signature vaccine injury clinic. The event featured a panel of individuals who described themselves as being harmed by vaccines. They sat behind placards that read "vaccine injured" while speaking with Kennedy and other senior Trump administration officials. Leslie argued that the high-profile nature of the event risks tarnishing the hospital, a facility often referred to as the "house of hope" by patients with rare conditions who have exhausted other treatment options.

Leslie acknowledged that some board members might prefer he avoid criticizing the secretary. However, he stated that remaining quiet would be a failure of the board's advisory role. "But I think that that would be a failing as an advisory board if we were silent," he said. He clarified that his objection was not to the scientific study of vaccine harms. Leslie emphasized that serious reactions are rare but real, and that patients who believe they have been injured should "be taken seriously."

Financial details provided during the meeting suggest the new clinic does not alter the hospital's current resources. Kennedy's addition comes with no new funding and no additional clinic space. This aligns with the existing infrastructure, as the NIH already maintains a center dedicated to studying vaccine injuries.

Jonathan Green, the hospital's chief executive officer, sat next to Leslie during the session and supported the financial assessment. Green noted that the NIH has researched vaccine safety and efficacy for decades and that this work continues. He characterized the new clinic as merely one more individual "protocol" within the hospital's research operations. Green's description contrasts with the ceremonial tone of the launch, framing the clinic as a modest extension of established research rather than a major new initiative.

The combined remarks from the board chair and the chief executive outline a distinction between the public perception of the clinic and its operational reality. Leslie focused on the potential reputational impact on a hospital serving vulnerable patients, while Green highlighted the clinic's status as a standard research component without additional budgetary weight. The board's discussion concluded with these two perspectives on the clinic's place within the institution.